IMITREX- sumatriptan succinate injection Stany Zjednoczone - angielski - NLM (National Library of Medicine)

imitrex- sumatriptan succinate injection

physicians total care, inc. - sumatriptan succinate (unii: j8bdz68989) (sumatriptan - unii:8r78f6l9vo) - sumatriptan 6 mg in 0.5 ml - imitrex injection is indicated for 1) the acute treatment of migraine attacks with or without aura and 2) the acute treatment of cluster headache episodes. imitrex injection is not for use in the management of hemiplegic or basilar migraine (see contraindications). imitrex injection should not be given intravenously because of its potential to cause coronary vasospasm. imitrex injection should not be given to patients with history, symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes. in addition, patients with other significant underlying cardiovascular diseases should not receive imitrex injection. ischemic cardiac syndromes include, but are not limited to, angina pectoris of any type (e.g., stable angina of effort, vasospastic forms of angina such as the prinzmetal variant), all forms of myocardial infarction, and silent myocardial ischemia. cerebrovascular syndromes include, but are not limited to, strokes of any type as well as transient ischemic attacks. peripheral v

TENOFOVIR EMT GH tenofovir disoproxil phosphate and emtricitabine 291mg/200mg film coated tablets Australia - angielski - Department of Health (Therapeutic Goods Administration)

tenofovir emt gh tenofovir disoproxil phosphate and emtricitabine 291mg/200mg film coated tablets

lupin australia pty limited - emtricitabine, quantity: 200 mg; tenofovir disoproxil phosphate, quantity: 291 mg - tablet, film coated - excipient ingredients: mannitol; purified water; colloidal anhydrous silica; croscarmellose sodium; microcrystalline cellulose; stearic acid; titanium dioxide; lactose monohydrate; hypromellose; triacetin; indigo carmine aluminium lake - treatment of hiv-1 infection tenofovir emt gh is indicated for the treatment of hiv infected adults over the age of 18 years, in combination with other antiretroviral agents.,pre-exposure prophylaxis tenofovir emt gh is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 in adults at high risk. this indication is based on clinical trials in men who have sex with men (msm) at high risk for hiv-1 infection and in heterosexual serodiscordant couples (see clinical studies).

TENOFOVIR DISOPROXIL EMTRICITABINE VIATRIS 300/200 tenofovir disoproxil maleate 300 mg and emtricitabine 200 mg film coated tablet bottle Australia - angielski - Department of Health (Therapeutic Goods Administration)

tenofovir disoproxil emtricitabine viatris 300/200 tenofovir disoproxil maleate 300 mg and emtricitabine 200 mg film coated tablet bottle

alphapharm pty ltd - emtricitabine, quantity: 200 mg; tenofovir disoproxil maleate, quantity: 300 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; colloidal anhydrous silica; iron oxide red; microcrystalline cellulose; hyprolose; titanium dioxide; hypromellose; triacetin; iron oxide yellow; brilliant blue fcf aluminium lake - treatment of hiv-1 infection: tenofovir disoproxil emtricitabine mylan 300/200 is indicated for the treatment of hiv infected adults over the age of 18 years, in combination with other antiretroviral agents. pre-exposure prophylaxis: tenofovir disoproxil emtricitabine mylan 300/200 is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 in adults at high risk. this indication is based on clinical trials in men who have sex with men (msm) at high risk for hiv-1 infection and in heterosexual serodiscordant couples (see clinical studies).

TRUVADA tenofovir disoproxil fumarate / emtricitabine 300/200 mg tablet bottle Australia - angielski - Department of Health (Therapeutic Goods Administration)

truvada tenofovir disoproxil fumarate / emtricitabine 300/200 mg tablet bottle

gilead sciences pty ltd - tenofovir disoproxil fumarate, quantity: 300 mg; emtricitabine, quantity: 200 mg - tablet, film coated - excipient ingredients: indigo carmine aluminium lake; magnesium stearate; croscarmellose sodium; titanium dioxide; triacetin; pregelatinised maize starch; microcrystalline cellulose; lactose monohydrate; hypromellose - treatment of hiv-1 infection,truvada is indicated for the treatment of hiv infected adults over the age of 18 years, in combination with other antiretroviral agents.,pre-exposure prophylaxis truvada is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 in adults at high risk. this indication is based on clinical trials in men who have sex with men (msm) at high risk for hiv-1 infection and in heterosexual serodiscordant couples (see clinical studies).

Tenofovir/Emtricitabine 300/200 ARX tenofovir disoproxil fumarate 300 mg emtricitabine 200 mg tablet bottle Australia - angielski - Department of Health (Therapeutic Goods Administration)

tenofovir/emtricitabine 300/200 arx tenofovir disoproxil fumarate 300 mg emtricitabine 200 mg tablet bottle

arrotex pharmaceuticals pty ltd - tenofovir disoproxil fumarate, quantity: 300 mg; emtricitabine, quantity: 200 mg - tablet, film coated - excipient ingredients: lactose; magnesium stearate; colloidal anhydrous silica; crospovidone; indigo carmine aluminium lake; macrogol 8000; purified talc; titanium dioxide; polyvinyl alcohol - tenofovir/emtricitabine 300/200 arx is indicated for the treatment of hiv infected adults over the age of 18 years, in combination with other antiretroviral agents.,pre-exposure prophylaxis tenofovir/emtricitabine 300/200 arx is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to redcue the risk of sexually acquired hiv-1 in adutls at high risk. this indication is based on clinical trials in men who have sex with men (msm) at high risk for hiv-1 infection and in heterosexual serodiscordant couples.

Tenofovir/Emtricitabine 300/200 ARX tenofovir disoproxil fumarate 300 mg emtricitabine 200 mg tablet blister pack Australia - angielski - Department of Health (Therapeutic Goods Administration)

tenofovir/emtricitabine 300/200 arx tenofovir disoproxil fumarate 300 mg emtricitabine 200 mg tablet blister pack

arrotex pharmaceuticals pty ltd - tenofovir disoproxil fumarate, quantity: 300 mg; emtricitabine, quantity: 200 mg - tablet, film coated - excipient ingredients: titanium dioxide; colloidal anhydrous silica; crospovidone; indigo carmine aluminium lake; macrogol 8000; lactose; polyvinyl alcohol; purified talc; magnesium stearate - tenofovir/emtricitabine 300/200 arx is indicated for the treatment of hiv infected adults over the age of 18 years, in combination with other antiretroviral agents.,pre-exposure prophylaxis tenofovir/emtricitabine 300/200 arx is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 in adults at high risk. this indication is based on clinical trials in men who have sex with men (msm) at high risk for hiv-1 infection and in heterosexual serodiscordant couples.

CLEVIPREX clevidipine, 50 mg in 100 mL injectable emulsion, Single Use Vials Australia - angielski - Department of Health (Therapeutic Goods Administration)

cleviprex clevidipine, 50 mg in 100 ml injectable emulsion, single use vials

chiesi australia pty ltd - clevidipine, quantity: 50 mg - injection, emulsion - excipient ingredients: soya oil; glycerol; egg lecithin; water for injections; sodium hydroxide; oleic acid; disodium edetate - cleviprex is indicated for the short term treatment of hypertension when oral therapy is not feasible or desirable.

CLEVIPREX clevidipine, 25 mg in 50 mL injectable emulsion, Single Use Vials Australia - angielski - Department of Health (Therapeutic Goods Administration)

cleviprex clevidipine, 25 mg in 50 ml injectable emulsion, single use vials

chiesi australia pty ltd - clevidipine, quantity: 25 mg - injection, emulsion - excipient ingredients: water for injections; glycerol; soya oil; egg lecithin; sodium hydroxide; oleic acid; disodium edetate - cleviprex is indicated for the short term treatment of hypertension when oral therapy is not feasible or desirable.

ESCIPREX DISTAB 5 Milligram Orodispersible Tablet Irlandia - angielski - HPRA (Health Products Regulatory Authority)

esciprex distab 5 milligram orodispersible tablet

rowex ltd - escitalopram oxalate - orodispersible tablet - 5 milligram - selective serotonin reuptake inhibitors

ESCIPREX DISTAB 10 Milligram Orodispersible Tablet Irlandia - angielski - HPRA (Health Products Regulatory Authority)

esciprex distab 10 milligram orodispersible tablet

rowex ltd - escitalopram oxalate - orodispersible tablet - 10 milligram - selective serotonin reuptake inhibitors